Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 3—March 2014
Research

Comparison of Imported Plasmodium ovale curtisi and P. ovale wallikeri Infections among Patients in Spain, 2005–2011

Gerardo Rojo-MarcosComments to Author , José Miguel Rubio-Muñoz, Germán Ramírez-Olivencia, Silvia García-Bujalance, Rosa Elcuaz-Romano, Marta Díaz-Menéndez, María Calderón, Isabel García-Bermejo, José Manuel Ruiz-Giardín, Francisco Jesús Merino-Fernández, Diego Torrús-Tendero, Alberto Delgado-Iribarren, Mónica Ribell-Bachs, Juan Arévalo-Serrano, and Juan Cuadros-González
Author affiliations: Príncipe de Asturias University Hospital, Madrid, Spain (G. Rojo-Marcos, J. Arévalo-Serrano, J. Cuadros-González,); Instituto de Salud Carlos III, Madrid (J.M. Rubio-Muñoz); Carlos III Hospital, Madrid (G. Ramírez-Olivencia); La Paz University Hospital, Madrid (S García-Bujalance); Doctor Negrín University Hospital, Las Palmas de Gran Canaria, Spain (R. Elcuaz-Romano); Ramón y Cajal Hospital, Madrid (M. Díaz-Menéndez); Gregorio Marañón University Hospital, Madrid (M. Calderón); Getafe University Hospital, Madrid (I. García-Bermejo); University Hospital of Fuenlabrada, Madrid (J. M. Ruiz-Giardín); Severo Ochoa University Hospital, Madrid (F.J. Merino-Fernández); University General Hospital of Alicante, Alicante, Spain (D. Torrús-Tendero); University Hospital Fundación Alcorcón, Madrid (A. Delgado-Iribarren); Hospital General de Granollers, Barcelona, Spain (M. Ribell-Bachs).

Main Article

Table 1

Demographic and epidemiologic characteristics of patients with imported Plasmodium ovale curtisi or Povale wallikeri infections, Spain, 2005–2011*

Characteristic P. ovale curtisi, n = 21 P. ovale wallikeri, n = 14 p value
Patient sex 0.332
M 10 (47.6) 9 (64.3)
F
 11 (52.4)
 5 (35.7 )
Patient age, y, median (IQR) 36.50 (23.04–52.66) 38.33 (11.79–45.27) 0.377
Age <15
 3 (14.3)
 4 (28.6)
 0.401
Ethnicity 0.721
Black 15 (71.4) 9 (64.3)
White
 6 (28.6)
 5 (35.7)
Type of patient 0.260
Early immigrant 6 (28.6) 4 (28.6)
Traveler 14 (66.7) 10 (71.4)
Reason for travel
Visiting friends and relatives 9 (42.8) 7 (50.0)
Tourism 1 (7.1)
Work 3 (14.3) 2 (14.3)
Cooperation 2 (9.5)
Unknown 1 (4.8)
Duration of travel, d, median (IQR)
 75 (23.25–91.50)
 23 (15.00–81.50)
 0.279
Country of infection 0.486
Equatorial Guinea 12 (57.1) 7 (50.0)
Nigeria 2 (9.5) 3 (21.4)
Equatorial Guinea or Cameroon 1 (4.8) 0
Ghana 1 (4.8) 1 (7.1)
Ethiopia 1 (4.8) 0
Guinea-Conakry 1 (4.8) 0
Liberia 1 (4.8) 0
Angola 1 (4.8) 0
Guinea-Bissau 1 (4.8) 0
Guinea-Conakry or Senegal 0 1 (7.1)
Côte d’Ivoire 0 1 (7.1)
Mozambique
 0
 1 (7.1)
Chemoprophylaxis 0.627
No prophylaxis 17 (81.0) 13 (92.9)
Mefloquine, incomplete 1 (4.8) 1 (7.1)
Mefloquine 1 (4.8) 0
Doxycycline 1 (4.8) 0
Atovaquone/proguanil
 1 (4.8)
 0
Days from arrival to onset of symptoms, median (IQR) 94.5 (12.5–297.2) 9.5 (2.7–58.2) 0.077
Days from onset of symptoms to diagnosis, median (IQR) 8 (2.7–16.5) 3.5 (2.0–7.7) 0.206
Recent Plasmodium infection
 3 (14.3)
 3 (21.4)
 >0.999
Other infections
Hepatitis B virus >0.999
Active 1/11 (9.1) 0/10
Cured or vaccinated 6/11 (54.5) 5/10 (50.0)
Negative 4/11 (36.4) 5/10 (50.0)
Hepatitis C virus 1/7 (14.3) 0/10 0.412
HIV 1/7 (14.3) 0/10 0.412
Filariasis† 3/6 (50.0) 0/4 0.200
Intestinal parasites‡
 3/6 (50.0)
 1/4 (25.0)
 0.571
Other underlying conditions 9 (42.8) 6 (42.8) >0.999
Diabetes mellitus 2 (9.5) 1 (7.1)
Drepanocytosis 2 (9.5) 0
Hypertension 4 (19.0) 2 (14.3)
Obesity 1 (4.8) 0
Acute pancreatitis 0 1 (7.1)
Policystosis and nephrectomy 0 1 (7.1)
Oligoarthritis
 0
 1 (7.1)
Glucose-6-phosphate dehydrogenase deficiency 2/14 (14.3) 0/8 0.515
Pregnancy 1 (4.8) 0 >0.999

*Values are no. (%) patients or no. positive/total no. (%) patients unless otherwise indicated. IQR, interquartile range.
†Mansonella perstans (n = 2), Loa loa (n = 1).
‡Trichiuris trichiura (n = 3), hookworms (n = 2), Ascaris lumbricoides (n = 2), Strongyloides stercoralis (n = 1), Entamoeba hystolitica (n = 1).

Main Article

Page created: February 19, 2014
Page updated: February 19, 2014
Page reviewed: February 19, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external